ENOVNYSEOrthopedic, Prosthetic & Surgical Appliances & SuppliesFiscal year ends December 31
Enovis CORP
Financials through Q2 FY2026, quarter ended Jul 3, 2026Last filing: 10-Q on Aug 6, 2026
$19.87+0.28 (+1.43%)
Close on Oct 19, 2026
- Market cap
- $1.14B
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
59.8%+6.0 pts over 5 years
Operating margin
-50.0%−44.1 pts over 5 years
Net margin
-52.7%−56.5 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +6.7% | +12.9% | +14.9% | -4.1% | |
| Gross profit | +13.9% | +15.7% | +17.4% | +2.3% | |
| Free cash flow | – | – | -36.1% | -21.8% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 4.3% | 1.2% | -58.5% | |
| Return on assets | 2.0% | 0.6% | -27.7% | |
| Current ratio | 1.64 | 1.68 | 2.02 | |
| Debt to equity | 0.45 | 0.63 | 0.87 | |
| Net debt to EBITDA | 2.96× | 20.98× | 5.73× | |
| Interest coverage | 7.8× | -1.3× | -32.3× | |
| Inventory turnover | 5.6× | 0.9× | 1.6× | |
| Capex to revenue | 2.0% | 10.2% | 8.8% | |
| Diluted shares | 41M | 46M | 57M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Enovis generated $877.75M from operations and spent $718.28M on capital expenditure, dividends and share buybacks. 99% of that went back into the business.
Generated
$877.75M
Used
$718.28M
Capital expenditure$710.00M99%Dividends$00%Share buybacks$8.28M1%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-52.7%
×Asset turnover0.53×
×Equity multiplier2.11×
=Return on equity, FY2025-58.5%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -52.7% | 0.53× | 2.11× | -58.5% |
| FY2024 | -39.2% | 0.46× | 1.54× | -27.6% |
| FY2023 | -1.9% | 0.39× | 1.28× | -1.0% |
| FY2022 | -0.9% | 0.24× | 1.59× | -0.3% |
| FY2021 | 5.0% | 0.18× | 1.94× | 1.8% |
| FY2020 | 3.8% | 0.15× | 2.11× | 1.2% |
| FY2019 | -15.9% | 0.48× | 2.09× | -15.7% |
| FY2018 | 6.4% | 0.33× | 1.97× | 4.1% |
| FY2017 | 7.8% | 0.30× | 2.04× | 4.7% |
| FY2016 | 4.0% | 0.49× | 2.19× | 4.3% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
4of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero-$1.18B
- Cash generatingOperating cash flow above zero$217.29M
- Return on assets improvedROA up on the prior year-18.3% → -25.1%
- Earnings backed by cashOperating cash flow above net income$217.29M vs -$1.18B
- Less leverageLong-term debt to assets fell27.8% → 32.9%
- Better liquidityCurrent ratio rose2.17 → 2.02
- No dilutionShare count did not rise55M → 57M
- Gross margin improvedGross margin up on the prior year56.02% → 59.84%
- More efficientAsset turnover rose0.47 → 0.48